Search filters

List of works by Hanna Berak

Analysis of genotype 1b hepatitis C virus IRES in serum and peripheral blood mononuclear cells in patients treated with interferon and ribavirin

scientific article

Better outcome of HBe Ag (-) than HBe Ag (+) lamivudine treatment of HBV chronically infected patients.

scientific article published in January 2010

Changes in patient profile, treatment effectiveness, and safety during 4 years of access to interferon-free therapy for hepatitis C virus infection

scientific article published on 07 February 2020

Comparison of 5'UTR and HVR1 of hepatitis c virus (HCV) in serum and peripheral blood mononuclear cells in the early phase of interferon and ribavirin treatment

scientific article published in January 2011

Comparison of early virologic response among patients with chronic hepatitis C infected with genotype non 2/3 treated with pegylated interferon alfa-2B and ribavirin in dependence with hepatic fibrosis stages

scientific article published in January 2006

Corrigendum: Next-generation Sequencing Analysis of New Genotypes Appearing During Antiviral Treatment of Chronic Hepatitis C Reveals that These Are Selected from Pre-existing Minor Strains

scientific article published on 11 January 2019

Decrease of T-cells exhaustion markers programmed cell death-1 and T-cell immunoglobulin and mucin domain-containing protein 3 and plasma IL-10 levels after successful treatment of chronic hepatitis C

scientific article published on 29 September 2020

Deep sequencing of hepatitis C virus hypervariable region 1 reveals no correlation between genetic heterogeneity and antiviral treatment outcome

scientific article

Distribution of HCV genotypes in Poland

scientific article published in January 2013

Effect of Peginterferon or Ribavirin Dosing on Efficacy of Therapy With Telaprevir in Treatment-Experienced Patients With Chronic Hepatitis C and Advanced Liver Fibrosis: A Multicenter Cohort Study.

scientific article

Effect of comedication on ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin therapy in chronic hepatitis C - a real-world study

scientific article published on 05 September 2019

Effectiveness and Safety of Pangenotypic Regimens in the Most Difficult to Treat Population of Genotype 3 HCV Infected Cirrhotics

scientific article

Effectiveness and safety of ledipasvir/sofosbuvir±ribavirin in the treatment of HCV infection: The real-world HARVEST study.

scientific article published on 26 May 2017

Efficacy of HCV treatment in Poland at the turn of the interferon era - the EpiTer study

scientific article published on 28 November 2016

Expression of programmed cell death protein 1 and T-cell immunoglobulin- and mucin-domain-containing molecule-3 on peripheral blood CD4+CD8+ double positive T cells in patients with chronic hepatitis C virus infection and in subjects who spontaneous

scientific article published on 29 April 2019

Factors influencing the failure of interferon-free therapy for chronic hepatitis C: Data from the Polish EpiTer-2 cohort study

scientific article published on 01 May 2021

HCV Genotype Has No Influence on the Incidence of Diabetes—EpiTer Multicentre Study

scientific article published on 13 January 2022

Hepatitis C Infection as a Risk Factor for Hypertension and Cardiovascular Diseases: An EpiTer Multicenter Study

scientific article published in September 2022

Hepatitis C virus (HCV) genotype 1b displays higher genetic variability of hypervariable region 1 (HVR1) than genotype 3

scientific article published on 06 September 2019

Is Interferon-Based Treatment of Viral Hepatitis C Genotype 3 Infection Still of Value in the Era of Direct-Acting Antivirals?

scientific article published in February 2018

Is an 8-week regimen of glecaprevir/pibrentasvir sufficient for all HCV infected patients in the real-world experience?

scientific article published on 10 November 2020

Low risk of HBV reactivation in a large European cohort of HCV/HBV coinfected patients treated with DAA

scientific article published on 13 June 2020

Pangenotypic and Genotype-Specific Antivirals in the Treatment of HCV Genotype 4 Infected Patients with HCV Monoinfection and HIV/HCV Coinfection

scientific article published on 13 January 2022

Peginterferon alfa-2a and peginterferon alfa-2b combined with ribavirin in patients with genotype 1 chronic hepatitis C: results of a prospective single-centre study.

scientific article published on 9 June 2014

Pegylated interferon-alfa 2a with ribavirin in chronic viral hepatitis C (final report)

scientific article

Prevalence of HCV genotypes in Poland - the EpiTer study

scientific article published on 28 November 2016

Randomized study of danoprevir/ritonavir-based therapy for HCV genotype 1 patients with prior partial or null responses to peginterferon/ribavirin.

scientific article published on 18 September 2014

Real-world experience with Grazoprevir/Elbasvir in the treatment of previously "difficult to treat" patients infected with hepatitis C virus genotype 1 and 4.

scientific article

Safety of peginterferon alfa-2a plus ribavirin in a large multinational cohort of chronic hepatitis C patients

scientific article

Study of the efficacy of combined therapy with interferon alfacon-1 and ribavirin for chronic hepatitis C

scientific article published in January 2006

The efficacy of paritaprevir/ritonavir/ombitasvir+dasabuvir and ledipasvir/sofosbuvir is comparable in patients who failed interferon-based treatment with first generation protease inhibitors - a multicenter cohort study

scholarly article by Ewa Janczewska et al published 16 November 2018 in BMC Infectious Diseases

Ultradeep pyrosequencing of hepatitis C virus hypervariable region 1 in quasispecies analysis

scientific article published on 28 April 2013

[Results of 48 weeks lamivudine treatment of patients with chronic hepatitis B and HBeAg (+)]

scientific article published on 01 January 2006

[Results of 48 weeks lamivudine treatment of patients with chronic hepatitis B and HBeAg (-)].

scientific article

Paulina is supported by:

About Paulina

Help